The Selective Arterial Calcium Injection Test is a Valid Diagnostic Method for Invisible Gastrinoma with Duodenal Ulcer Stenosis: A Case Report.

The localization and diagnosis of microgastrinomas in a patient with multiple endocrine neoplasia type 1 is difficult preoperatively. The selective arterial calcium injection (SACI) test is a valid diagnostic method for the preoperative diagnosis of these invisible microgastrinomas. We report a rare case of multiple invisible duodenal microgastrinomas with severe duodenal stenosis diagnosed preoperatively by using the SACI test. A 50-year-old man was admitted to our hospital with recurrent duodenal ulcers. His serum gastrin level was elevated to 730 pg/ml. It was impossible for gastrointestinal endoscopy to pass through to visualize the inferior part of the duodenum, because recurrent duodenal ulcers had resulted in severe duodenal stenosis. The duodenal stenosis also prevented additional endoscopic examinations such as endoscopic ultrasonography. Computed tomography did not show any tumors in the duodenum and pancreas. The SACI test provided the evidence for a gastrinoma in the vascular territory of the inferior pancreatic-duodenal artery. We diagnosed a gastrinoma in the peri- ampullary lesion, so we performed Subtotal Stomach-Preserving Pancreatico- duodenectomy with regional lymphadenectomy. Histopathological findings showed multiple duodenal gastrinomas with lymph node metastasis and nonfunctioning pancreatic neuroendocrine tumors. Twenty months after surgery, the patient is alive with no evidence of recurrence and a normal gastrin level. In conclusion, the SACI test can enhance the accuracy of preoperative localization and diagnosis of invisible microgastrinomas, especially in the setting of severe duodenal stenosis.

[1]  J. Bilezikian,et al.  Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). , 2012, The Journal of clinical endocrinology and metabolism.

[2]  T. Masaki,et al.  Multiple giant duodenal ulcers associated with duodenal gastrinoma , 2012, Clinical Journal of Gastroenterology.

[3]  M. Imamura,et al.  Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. , 2011, World journal of gastroenterology.

[4]  A. Tabarin,et al.  Risk Factors and Causes of Death in MEN1 Disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) Cohort Study Among 758 Patients , 2010, World Journal of Surgery.

[5]  M. Rothmund,et al.  Management of sporadic and multiple endocrine neoplasia type 1 gastrinomas , 2007, The British journal of surgery.

[6]  D. Dempsey Surgery Increases Survival in Patients With Gastrinoma , 2007 .

[7]  V. Gudziol,et al.  [Multiple endocrine neoplasia type 1]. , 2007, HNO.

[8]  M. Rothmund,et al.  Outcome of Duodenopancreatic Resections in Patients With Multiple Endocrine Neoplasia Type 1 , 2005, Annals of surgery.

[9]  M. Imamura,et al.  New Pancreas-preserving Total Duodenectomy Technique , 2005, World Journal of Surgery.

[10]  R. Jensen,et al.  Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. , 2001, The Journal of clinical endocrinology and metabolism.

[11]  Michelle A. Anderson,et al.  Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas , 2000, American Journal of Gastroenterology.